HIMSS TV is your Insider’s Guide to everything HIMSS. We are the world’s first online broadcasting network, focused on global innovation and how information and technology are driving change in healthcare.
  Home
Marketing microtargeting: Consumer motivations found in a tube of toothpaste
AI/ML

Marketing microtargeting: Consumer motivations found in a tube of toothpaste

2:10

Renown Health increased Medicare Advantage membership 4 percent by using data, analytics and outreach to get to know its consumer.

Read More
Read Less

AI/ML - Similar Videos View more in AI/ML

9:51

Charting digital medicine's top AI trends

Surgeon and futurist Dr. Shafi Ahmed talks about how AI is shaping healthcare's future, including its use in digital surgery, drug development, wearables, genomic medicine and clinical decision support.

Charting digital medicine's top AI trends
Surgeon and futurist Dr. Shafi Ahmed talks about how AI is shaping healthcare's future, including its use in digital surgery, drug development, wearables, genomic medicine and clinical decision support.
9:51
9:56

CIO Spotlight: Artesia General Hospital's Eric Jimenez

The chief information officer of the 25-bed New Mexico nonprofit discusses plan for some new clinical automation tools. He also describes how he's using AI to help with network defense, and how that's enabling gains in other areas.

CIO Spotlight: Artesia General Hospital's Eric Jimenez
The chief information officer of the 25-bed New Mexico nonprofit discusses plan for some new clinical automation tools. He also describes how he's using AI to help with network defense, and how that's enabling gains in other areas.
9:56
7:52

AI is driving down clinical denial rates

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.

AI is driving down clinical denial rates
Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.
7:52